The significant revenue beat and raised guidance reflect strong execution on international COVID vaccine deliveries and cost discipline. Watch for the November 12 Analyst Day for further pipeline details, particularly intismeran regulatory submission timing and propionic acidemia data.
Drugs in focus
MRNA drug pipeline →mRNA-1010
▲ Bullish Named in this 8-K- Impact
- Phase
- Filed / PDUFA (Phase 3 completed)
- Time to market
- PDUFA date is August 5, 2026. If approved, the vaccine could be available for the 2026/2027 Northern Hemisphere flu season. Regulatory submissions are also under review in Europe, Canada, and Australia, with potential approvals expected in 2026.
- Next catalyst
- None dated
What to watchWatch for the FDA decision by August 5, 2026. The unanimous 9-0 advisory committee vote on June 18 makes approval the base case, and the stock has already re-rated from a 52-week low of $22 to ~$71 on the expectation, so a positive decision may be partially priced in. Approval would unlock a new multi-billion-dollar TAM for Moderna beyond COVID; a surprise CRL would be a severe setback for the stock given how much of the 2026 rally is built on flu vaccine hopes.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 6 $254.19entry
- T+1 · 8d ago +5.83%α +3.46% · $269.00
- T+5 · 4d ago −12.12%α −14.72% · $223.37
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Moderna reported Q3 2026 revenue of $1.313B (consensus $890.2M) and GAAP diluted EPS of $0.38 (consensus $-1.25), a significant beat driven by higher COVID vaccine sales in international markets. The company raised its full-year 2026 revenue growth outlook to 15%-25% from up to 10%, improved its year-end cash balance forecast to $8.1B-$8.3B, and highlighted the FDA approval of mFLUSIVA and positive Phase 3 data for intismeran in melanoma.
Key Financial Metrics
Key Facts
- Q3 2026 total revenue $1.313B, up 29% YoY from $1.016B
- GAAP diluted EPS $0.38, compared to a loss per share of $(0.51) in Q3 2025
- Net income of $162M, compared to a net loss of $(200M) in Q3 2025
- 2026 revenue growth outlook raised to 15%-25%, exceeding prior expectation of up to 10% growth
- 2026 year-end cash and investments forecast raised to $8.1B-$8.3B from $4.7B-$5.2B
- R&D expenses decreased 27% YoY to $583M
- FDA approved mFLUSIVA (seasonal influenza vaccine) in August 2026, the company's fifth approved product globally
- Positive Phase 3 results for intismeran (mRNA-4157) in melanoma: reduced risk of recurrence or death by 42% vs KEYTRUDA alone
- Convertible notes offering raised approximately $2.6B in net proceeds in September 2026
- Litigation settlement with GSK on October 28, 2026, with patent cross-licenses and no payments
Financial Impact
Revenue beat consensus by $422.8M (47.5%); EPS surprise of $1.63 vs consensus estimate of -$1.25; full-year revenue growth outlook raised to 15%-25% from up to 10%
Risk Factors
- Norovirus vaccine (mRNA-1403) program uncertain after Phase 3 interim analysis failed to meet early success criteria
- Convertible notes add $3.0B in debt, increasing leverage and potential future dilution
- Revenue concentration remains heavily dependent on COVID vaccine sales, which are inherently seasonal and subject to demand variability
- Accounts receivable surged to $1.367B from $184M at year-end 2025, indicating significant uncollected Q3 revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001682852-26-000194 |
| Document: mrna-20261106.htm | 0001682852-26-000194 |
| Document: 0001682852-26-000194-index-headers.html | 0001682852-26-000194 |
| Document: 0001682852-26-000194-index.html | 0001682852-26-000194 |
| Document: 0001682852-26-000194.txt | 0001682852-26-000194 |
| 8-K Data (Synthetic) | 0001682852-26-000194 |
Track record
26 reports on MRNA
5 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +14.15% at T+60 after the Mar 5, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 3/10 Entry $217.29 Now $215.27 −0.93% settles Nov 17
- Nov 13, 20263d ago 8-K Neutral 3/10 Entry $222.50 Now $215.27 −3.25% settles Nov 17
- Nov 6, 202610d ago 8-K Bullish 7/10 Viewing Entry $254.19 to $269.00 Now $215.27 −15.31% ▲ +5.83% +3.46% vs SPY
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $241.46 to $254.19 Now $215.27 −10.85% ▲ +5.27% +4.96% vs SPY
- Oct 28, 202619d ago Institutional Cluster Neutral 3/10 Entry $214.17 to $222.76 Now $215.27 +0.52% ▲ +4.01% +4.40% vs SPY
- Oct 27, 202620d ago ANALYST-DOWNGRADE Bearish 4/10 Entry $207.97 to $214.17 Now $215.27 −3.51% ▼ −2.98% −2.63% vs SPY
- Sep 30, 20266w ago 8-K Neutral 3/10 Entry $192.57 to $188.94 Now $215.27 +11.79% ▼ −1.89% −2.06% vs SPY
- Sep 30, 20266w ago ANALYST-DOWNGRADE Bearish 4/10 No price data
- Sep 16, 20268w ago Insider Cluster Bearish 5/10 Entry $158.07 to $154.04 Now $215.27 −36.19% ▲ +2.55% +2.43% vs SPY
- Sep 3, 202610w ago ANALYST-DOWNGRADE Bearish 6/10 Entry $148.87 to $145.55 Now $215.27 −44.60% ▲ +2.23% +1.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers